The Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathological Anatomy (SEAP-IAP) point out that Spain is making progress in the adoption of precision oncology, although notable differences persist depending on the size of the hospital and a generalized shortage of human resources, since 90 percent of centers consider that their staffing is insufficient.
These conclusions come from the second edition of the report "Implementation and regulation of Precision Oncology in Spain," presented this Wednesday, which examines the situation in 116 hospitals in eight autonomous communities and compares it with the snapshot from the previous year, when the first document had a smaller participation of centers and administrations.
SEOM president Javier de Castro has emphasized that precision oncology makes it possible to refine the diagnosis much more accurately of the type of tumor, facilitates access to targeted therapies, and opens the door to participation in clinical trials, which results in innovation in both therapeutic and diagnostic terms. In his view, all of this translates into more appropriate care for patients.
The report notes an "extensive" implementation of precision oncology. Seventy-six percent of the hospitals surveyed have a specific strategic plan for precision medicine or are in the process of developing one. In addition, 87 percent have access to next-generation sequencing (NGS), a key tool for molecular diagnosis, and 84 percent have the Common Catalog of Genetic and Genomic Tests of the National Health System (SNS).
Progress has been especially notable in medium-sized hospitals, defined as those with fewer than 500 beds, a relevant fact if one takes into account that half of oncology patients are treated in them. In these centers, strategic plans have gone from 35.5 percent to 42 percent, while the implementation of the common tests catalog has grown to 82 percent, compared with 67.7 percent recorded in the previous year.
However, with regard to access to molecular diagnosis, only 22 percent of medium-sized hospitals perform sequencing in their own laboratory, compared with 100 percent of very large centers, considered to be those with more than 1,000 beds. Sixty-five percent of medium-sized hospitals refer these tests to other centers, a resource that no large hospital uses.
The document devotes special attention to liquid biopsy and states that 77 percent of hospitals have some type of access to this technique, although it is only applied routinely in eight percent of centers.
According to the report, 93 percent of hospitals perceive relevant clinical improvements with the incorporation of precision oncology, regardless of their size. Similarly, 78 percent rate the impact on patients’ survival and quality of life positively.
Areas for improvement and insufficient resources
Despite the advances, the report identifies various areas for improvement, starting with the need to reduce differences between hospitals and strengthen the human and material resources allocated to precision oncology. None of the participating communities considers the demand for personnel to be covered, and only eight percent of centers say they have an adequate workforce.
At the same time, economic and technological limitations are detected that make optimal implementation difficult. Specifically, 73 percent of hospitals indicate economic-type obstacles and 45 percent point to the lack of technology as another significant barrier.
The Molecular Tumor Committees, key structures for interpreting and translating into clinical practice the results of the tests, are present in 69 percent of centers. In practically all of them, specialists in medical oncology and pathologic anatomy participate, and to a lesser extent, professionals in molecular biology, hospital pharmacy, genetics, and molecular biochemistry.
However, the real impact of these committees is scarcely evaluated: 56 percent of hospitals that have this structure do not know what percentage of their recommendations translates into effective changes in patients’ treatment.
In this vein, the report emphasizes that one of the main weaknesses lies in the low measurement of the impact of results. For this reason, the document’s coordinator, Ramón Colomer, has raised the need to define indicators, especially related to timelines, and monitor them systematically, with special attention to mid-sized hospitals.
Also, a margin for improvement is detected in the formalization of the quality of the tests. Seventy-seven percent of the laboratories participate in external quality control programs, while ISO 9001 certification is achieved in 43 percent and specific ISO 15189 accreditation, the strictest for clinical laboratories, only reaches 27 percent.
Recommendations to consolidate precision oncology
SEOM and SEAP-IAP have presented a battery of recommendations to strengthen precision oncology across the entire territory. First, they propose completing and making public the autonomous strategies for precision medicine, since five of the eight communities analyzed have them and the other three have them in the development phase.
Likewise, they call for closing the existing gap in the Common Catalogue of Genetic and Genomic Tests regarding determinations that are not yet fully implemented in all centers, to promote laboratory accreditation, to set maximum response times, and to address in a specific manner access to precision oncology in medium-sized hospitals.
Among the proposals is also consolidating the existence of a Molecular Tumors Committee in all centers, increasing training in precision oncology, strengthening funding, defining a minimum set of indicators and publishing the results periodically, as well as incorporating liquid biopsy into the portfolio of services with clearly defined indications.
To conclude, the scientific societies express their confidence that the report will serve as a lever so that the autonomous communities that still do not have a strategic plan will promote it and use it as a basis to meet the needs identified. De Castro has stressed that "it is not only about implementing technologies, but a structure" that guarantees equitable access to these advances for all patients.